Skip to content

Assess the efficacy of hemoperfusion treatment on improving the survial of maintenance hemodialysis (MHD) patients: A randomized, open-label, parallel-group, multicenter study

Assess the efficacy of hemoperfusion treatment on improving the survial of maintenance hemodialysis (MHD) patients: A randomized, open-label, parallel-group, multicenter study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009332
Enrollment
Unknown
Registered
2016-10-08
Start date
2014-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance Hemodialysis Patients (MHD)

Interventions

HD group:HD, 2-3 times a week
HF/HDF, 1 time a week
HP group:HD, 2-3 times a week
HP, 1 time every 2 week

Sponsors

Xinhua Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75y, male or female; 2. Maintenance hemodialysis duration=2y; 3. Regular hemodialysis, 2-3 times a week, 4-5h per session; 4. Kt/v=1.2; 5. Written informed consent signed.

Exclusion criteria

Exclusion criteria: 1. life expectancygrade 3); 6. active or chronic gastrointestinal bleeding, or a clear coagulation dysfunction; 7. malignant tumor, active infection; 8. pregnancy or lactation; 9. participat in clinical trials in last 3 months or undergoing clinical trials; 10. unwilling or unable to comply with the research program; 11. not suitable for this trial.

Design outcomes

Primary

MeasureTime frame
all-cause mortality;cardiovascular mortality;

Secondary

MeasureTime frame
cardiovascular events;

Countries

China

Contacts

Public ContactGengru Jiang

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

jianggeng-ru@hotmail.com+86 13816238339

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026